National guidance conflicts regarding the use of RhD immune globulin administration <12w. Recent Society for Maternal Fetal Medicine (SMFM) guidelines suggest liberal use of this product while other guidelines, including Society of Family Planning and the World Health Organization, propose a more conservative approach. Medicine is not practiced in a vacuum, and potential harms must include not only individual but communal and public health effects. We aim to critically examine the practical implications of the new SMFM guidelines with a focus on equity and access.

2015-02-01·Seminars in Fetal and Neonatal Medicine2区 · 医学

Impact of Rhesus disease on the global problem of bilirubin-induced neurologic dysfunction

2区 · 医学

Review

作者: Zipursky, Alvin ; Bhutani, Vinod K

Clinical experience with Rhesus (Rh) disease and its post-icteric sequelae is limited among high-income countries because of nearly over four decades of effective prevention care. We hypothesized that Rh disease is prevalent in other regions of the world because it is likely that protection is limited or non-existent. Following a worldwide study, it has been concluded that Rh hemolytic disease is a significant public health problem resulting in stillbirths and neonatal deaths, and is a major cause of severe hyperbilirubinemia with its sequelae, kernicterus and bilirubin-induced neurologic dysfunction. Knowing that effective Rh-disease prophylaxis depends on maternal blood-type screening, healthcare afforded to the high-risk mothers needs to be free of bottlenecks and coupled with unfettered access to effective Rh-immunoglobulin. Future studies that match the universal identification of Rh-negative status of women and targeted use of immunoprophylaxis to prevent childhood bilirubin neurotoxicity are within reach, based on vast prior experiences.

2006-03-01·Best Practice & Research Clinical Haematology4区 · 医学

Rh-immunoglobulin: Rh prophylaxis

4区 · 医学

Review

作者: Bowman, John

A review.The development of Rh Ig has been a major landmark in preventive medicine.Before its introduction, the Rh immunization rate was 13.2% per Rh-pos. pregnancy.Subsequent to introduction, the Rh immunization rate has been reduced to 0.14%.The failures are due to Rh immunization before 28 wk' gestation.The success rate of Rh immunoprophylaxis is 98.4-99%.

100 项与人免疫球蛋白气雾剂相关的药物交易

登录后查看更多信息